Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Prenatal testing
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== Advances in prenatal screening ==== Measurement of [[fetal protein]]s in maternal serum is a part of standard prenatal screening for [[Diagnosis of fetal aneuploidy|fetal aneuploidy]] and [[neural tube defects]].<ref>{{cite journal |display-authors=6 |vauthors=Ball RH, Caughey AB, Malone FD, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Emig D, D'Alton ME |date=July 2007 |title=First- and second-trimester evaluation of risk for Down syndrome |journal=Obstetrics and Gynecology |volume=110 |issue=1 |pages=10β7 |doi=10.1097/01.AOG.0000263470.89007.e3 |pmid=17601890 |s2cid=10885982}}</ref><ref>{{cite journal |vauthors=Dashe JS, Twickler DM, Santos-Ramos R, McIntire DD, Ramus RM |date=December 2006 |title=Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound |url=http://rc.kfshrc.edu.sa/rcf/E_Library/NTDR/Alphafeto%20protein%20detection..pdf |url-status=dead |journal=American Journal of Obstetrics and Gynecology |volume=195 |issue=6 |pages=1623β8 |doi=10.1016/j.ajog.2006.03.097 |pmid=16769022 |archive-url=https://web.archive.org/web/20111001101304/http://rc.kfshrc.edu.sa/rcf/E_Library/NTDR/Alphafeto%20protein%20detection..pdf |archive-date=October 1, 2011 |access-date=November 12, 2010}}</ref> Computational predictive model shows that extensive and diverse feto-maternal protein trafficking occurs during pregnancy and can be readily detected non-invasively in maternal [[whole blood]].<ref>{{cite journal |vauthors=Maron JL, Alterovitz G, Ramoni M, Johnson KL, Bianchi DW |date=December 2009 |title=High-throughput discovery and characterization of fetal protein trafficking in the blood of pregnant women |journal=Proteomics. Clinical Applications |volume=3 |issue=12 |pages=1389β96 |doi=10.1002/prca.200900109 |pmc=2825712 |pmid=20186258}}</ref> This computational approach circumvented a major limitation, the abundance of maternal proteins interfering with the detection of fetal proteins, to fetal proteomic analysis of maternal blood. Entering fetal gene transcripts previously identified in maternal whole blood into a computational predictive model helped develop a comprehensive proteomic network of the term neonate. It also shows that the fetal proteins detected in pregnant woman's blood originate from a diverse group of tissues and organs from the developing fetus. Development proteomic networks dominate the functional characterization of the predicted proteins, illustrating the potential clinical application of this technology as a way to monitor normal and abnormal fetal development.{{cn|date=February 2025}} The difference in [[DNA methylation|methylation]] of specific DNA sequences between mother and fetus can be used to identify fetal-specific DNA in the blood circulation of the mother. In a study published in the March 6, 2011, online issue of ''[[Nature (journal)|Nature]]'', using this non-invasive technique a group of investigators from Greece and UK achieved correct diagnosis of 14 [[trisomy 21]] ([[Down syndrome]]) and 26 normal cases.<ref>{{cite journal |vauthors=Papageorgiou EA, Karagrigoriou A, Tsaliki E, Velissariou V, Carter NP, Patsalis PC |date=April 2011 |title=Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21 |journal=Nature Medicine |volume=17 |issue=4 |pages=510β3 |doi=10.1038/nm.2312 |pmc=3977039 |pmid=21378977}}</ref><ref>{{cite web |title=A New Non-invasive Test for Down Syndrome:Trisomy 21 Diagnosis using Fetal-Specific DNA Methylation |url=http://www.sciguru.com/newsitem/6740/A-New-Non-invasive-Test-for-Down-SyndromeTrisomy-21-Diagnosis-using-Fetal-Specific-DNA-Methylation/ |access-date=March 8, 2011 |publisher=SciGuru.com}}</ref> Using [[massive parallel sequencing]], a study testing for trisomy 21 only, successfully detected 209 of 212 cases (98.6%) with 3 false-positives in 1,471 pregnancies (0.2%).<ref name="Palomaki" /> With commercially available non-invasive (blood) testing for Down syndrome having become available to patients in the United States and already available in China, in October 2011, the International Society for Prenatal Diagnosis created some guidance. Based on its [[sensitivity and specificity]], it constitutes an advanced screening test and that positive results require confirmation by an invasive test, and that while effective in the diagnosis of Down syndrome, it cannot assess half the abnormalities detected by invasive testing. The test is not recommended for general use until results from broader studies have been reported, but may be useful in high-risk patients in conjunction with genetic counseling.<ref name="ISPD" /> A study in 2012 found that the maternal plasma cell-free DNA test was also able to detect trisomy 18 (Edwards syndrome) in 100% of the cases (59/59) at a false-positive rate of 0.28%, and trisomy 13 (Patau syndrome) in 91.7% of the cases (11/12) at a false-positive rate of 0.97%. The test interpreted 99.1% of samples (1,971/1,988); among the 17 samples without an interpretation, three were trisomy 18. The study stated that if z-score cutoffs for trisomy 18 and 13 were raised slightly, the overall false-positive rates for the three aneuploidies could be as low as 0.1% (2/1,688) at an overall detection rate of 98.9% (280/283) for common aneuploidies (this includes all three trisomies: Down, Edwards and Patau).<ref>{{cite journal |display-authors=6 |vauthors=Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA |date=March 2012 |title=DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study |journal=Genetics in Medicine |volume=14 |issue=3 |pages=296β305 |doi=10.1038/gim.2011.73 |pmc=3938175 |pmid=22281937}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)